Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial

Lancet

Volumn 364, Issue 9447, 2004, Pages 1757-1765

  Harper, Diane M ^a   Franco, Eduardo L ^b   Wheeler, Cosette ^c   Ferris, Daron G ^d   Jenkins, David ^e   Schuind, Anne ^f   Zahaf, Toufik ^e   Innis, Bruce ^f   Naud, Paulo ^g   De Carvalho, Newton S ^h   Roteli Martins, Cecilia M ⁱ   Teixeira, Julio ^j   Blatter, Mark M ^k   Korn, Abner P ^l   Quint, Wim ^m   Dubin, Gary ^f  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f GLAXOSMITHKLINE   (United States)

^g FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ LM de Barros Hospital   (Brazil)

^j UNIVERSITY OF CAMPINAS   (Brazil)

^k Primary Physicians Research   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Delft Diagnostic Laboratory   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BODY TEMPERATURE; BRAZIL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NORTH AMERICA; PERSISTENT INFECTION; PRECANCER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPONTANEOUS ABORTION; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 8444249386     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17398-4     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:2001;153-156
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 37:(suppl 8):2001;S4-66
3. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 109:2004;418-424
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19
5. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:2003;518-527
6. Bosch FX, De Sanjose S. Human papillomavirus in cervical cancer. Curr Oncol Rep. 4:2002;175-183
7. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 164:2001;1017-1025
8. Schlecht NF, Platt RW, Negassa A, et al. Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. Am J Epidemiol. 158:2003;878-886
9. Bosch FX, De Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003: 3-13.
10. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802
11. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88:2003;63-73
12. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 89:2003;101-105
13. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 127:2003;930-934
14. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 93:2001;284-292
15. Schiller JT, and Lowy DR. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001: 50-4.
16. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:2002;1645-1651
17. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed - biologic concordance and women's preferences. Am J Obstet Gynecol. 186:2002;365-373
18. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 153:1998;1731-1739
19. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 40:2002;979-983
20. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol. 194:2001;51-58
21. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 37:1999;2508-2517
22. Baay MF, Quint WG, Koudstaal J, et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol. 34:1996;745-747
23. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 12:2003;485-490
24. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 190:2004;37-45
25. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556
26. Woodman CB, Collins S, Rollason TP, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet. 361:2003;40-43
27. Wheeler CM, Greer CE, Becker TM, Hunt WC, Anderson SM, Manos MM. Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet Gynecol. 88:1996;261-268
28. Harper DM, Longacre MR, Noll WW, Belloni DR, Cole BF. Factors affecting the detection rate of human papillomavirus. Ann Fam Med. 1:2003;221-227
29. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr. 31:2003;111-116
30. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol. 6:1995;495-524
31. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 30:(suppl 3):2000;266-270
32. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 347:2002;1652-1661
33. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 3:2003;469-475
34. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco EA. comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 106:10-10-2003;896-904
35. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med. 55:2004;319-331
36. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol. 15:2004;197-200
37. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer. 111:20-8-2004;278-285
38. Department of Health and Human Services, Centers for Disease Control and Prevention Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting. http://www.cdc.gov/nchstp/ dstd/Reports_Publications/99HPVReport.htm (accessed Oct 25, 2004).